485 related articles for article (PubMed ID: 26731167)
1. Discovery of 2-(2-aminopyrimidin-5-yl)-4-morpholino-N-(pyridin-3-yl)quinazolin-7-amines as novel PI3K/mTOR inhibitors and anticancer agents.
Peng W; Tu ZC; Long ZJ; Liu Q; Lu G
Eur J Med Chem; 2016 Jan; 108():644-654. PubMed ID: 26731167
[TBL] [Abstract][Full Text] [Related]
2. Discovery of 1-(3-aryl-4-chlorophenyl)-3-(p-aryl)urea derivatives against breast cancer by inhibiting PI3K/Akt/mTOR and Hedgehog signalings.
Li W; Sun Q; Song L; Gao C; Liu F; Chen Y; Jiang Y
Eur J Med Chem; 2017 Dec; 141():721-733. PubMed ID: 29107429
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel 1,3,5-triazine derivatives as potent inhibitor of cervical cancer via dual inhibition of PI3K/mTOR.
Hu J; Zhang Y; Tang N; Lu Y; Guo P; Huang Z
Bioorg Med Chem; 2021 Feb; 32():115997. PubMed ID: 33440319
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and biological evaluation of novel 4-alkynyl-quinoline derivatives as PI3K/mTOR dual inhibitors.
Lv X; Ying H; Ma X; Qiu N; Wu P; Yang B; Hu Y
Eur J Med Chem; 2015 Jun; 99():36-50. PubMed ID: 26046312
[TBL] [Abstract][Full Text] [Related]
5. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
Niu NK; Wang ZL; Pan ST; Ding HQ; Au GH; He ZX; Zhou ZW; Xiao G; Yang YX; Zhang X; Yang T; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1555-84. PubMed ID: 25792811
[TBL] [Abstract][Full Text] [Related]
6. Benzo[b]furan derivatives induces apoptosis by targeting the PI3K/Akt/mTOR signaling pathway in human breast cancer cells.
Kamal A; Lakshma Nayak V; Nagesh N; Vishnuvardhan MV; Subba Reddy NV
Bioorg Chem; 2016 Jun; 66():124-31. PubMed ID: 27149364
[TBL] [Abstract][Full Text] [Related]
7. Dual inhibition of PI3K and mTOR mitigates compensatory AKT activation and improves tamoxifen response in breast cancer.
Chen X; Zhao M; Hao M; Sun X; Wang J; Mao Y; Zu L; Liu J; Shen Y; Wang J; Shen K
Mol Cancer Res; 2013 Oct; 11(10):1269-78. PubMed ID: 23814023
[TBL] [Abstract][Full Text] [Related]
8. Novel 4-aminoquinazoline derivatives induce growth inhibition, cell cycle arrest and apoptosis via PI3Kα inhibition.
Fan YH; Ding HW; Liu DD; Song HR; Xu YN; Wang J
Bioorg Med Chem; 2018 May; 26(8):1675-1685. PubMed ID: 29475582
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antitumor activity evaluation of PI3K inhibitors containing 3-substituted quinazolin-4(3H)-one moiety.
Zhang H; Xin MH; Xie XX; Mao S; Zuo SJ; Lu SM; Zhang SQ
Bioorg Med Chem; 2015 Dec; 23(24):7765-76. PubMed ID: 26652969
[TBL] [Abstract][Full Text] [Related]
10. Novel anti-prostate cancer scaffold identified by the combination of in silico and cell-based assays targeting the PI3K-AKT-mTOR pathway.
Saidel MÉ; Dos Santos KC; Nagano LFP; Montanari CA; Leitão A
Bioorg Med Chem Lett; 2017 Sep; 27(17):4001-4006. PubMed ID: 28774426
[TBL] [Abstract][Full Text] [Related]
11. PI3Kδ and mTOR dual inhibitors: Design, synthesis and anticancer evaluation of 3-substituted aminomethylquinoline analogues.
Yevale D; Teraiya N; Lalwani T; Dalasaniya M; Kapadiya K; Ameta RK; Sangani CB; Duan YT
Bioorg Chem; 2024 Jun; 147():107323. PubMed ID: 38583254
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere.
Shao T; Wang J; Chen JG; Wang XM; Li H; Li YP; Li Y; Yang GD; Mei QB; Zhang SQ
Eur J Med Chem; 2014 Mar; 75():96-105. PubMed ID: 24530495
[TBL] [Abstract][Full Text] [Related]
13. Structural optimization towards promising β-methyl-4-acrylamido quinoline derivatives as PI3K/mTOR dual inhibitors for anti-cancer therapy: The in vitro and in vivo biological evaluation.
He R; Xu B; Ping L; Lv X
Eur J Med Chem; 2021 Mar; 214():113249. PubMed ID: 33561608
[TBL] [Abstract][Full Text] [Related]
14. Potent inhibitors of phosphatidylinositol 3 (PI3) kinase that have antiproliferative activity only when delivered as prodrug forms.
O'Brien NJ; Amran S; Medan J; Cleary B; Deady LW; Jennings IG; Thompson PE; Abbott BM
ChemMedChem; 2013 Jun; 8(6):914-8. PubMed ID: 23568455
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors.
Fan YH; Li W; Liu DD; Bai MX; Song HR; Xu YN; Lee S; Zhou ZP; Wang J; Ding HW
Eur J Med Chem; 2017 Oct; 139():95-106. PubMed ID: 28800461
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis and biological evaluation of thieno[3,2-d]pyrimidine derivatives containing aroyl hydrazone or aryl hydrazide moieties for PI3K and mTOR dual inhibition.
Han Y; Tian Y; Wang R; Fu S; Jiang J; Dong J; Qin M; Hou Y; Zhao Y
Bioorg Chem; 2020 Nov; 104():104197. PubMed ID: 32927132
[TBL] [Abstract][Full Text] [Related]
17. Discovery of benzenesulfonamide derivatives as potent PI3K/mTOR dual inhibitors with in vivo efficacies against hepatocellular carcinoma.
Chen Y; Zhang L; Yang C; Han J; Wang C; Zheng C; Zhou Y; Lv J; Song Y; Zhu J
Bioorg Med Chem; 2016 Mar; 24(5):957-66. PubMed ID: 26819001
[TBL] [Abstract][Full Text] [Related]
18. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel antitumor nitric oxide-donating β-elemene hybrids through inhibiting the PI3K/Akt pathway.
Chen J; Wang T; Xu S; Zhang P; Lin A; Wu L; Yao H; Xie W; Zhu Z; Xu J
Eur J Med Chem; 2017 Jul; 135():414-423. PubMed ID: 28463784
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of novel pyrazolochalcones as potential modulators of PI3K/Akt/mTOR pathway and inducers of apoptosis in breast cancer cells.
Shaik AB; Rao GK; Kumar GB; Patel N; Reddy VS; Khan I; Routhu SR; Kumar CG; Veena I; Chandra Shekar K; Barkume M; Jadhav S; Juvekar A; Kode J; Pal-Bhadra M; Kamal A
Eur J Med Chem; 2017 Oct; 139():305-324. PubMed ID: 28803046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
